AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

Simon Lovestone, Paul Francis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, Hilkka Soininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Malcolm Ward

Research output: Chapter in Book/Report/Conference proceedingConference paper

168 Citations (Scopus)


There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.
Original languageEnglish
Title of host publicationUnknown
Place of PublicationOXFORD
PublisherBlackwell Publishing
Pages36 - 46
Number of pages11
ISBN (Print)978-1-57331-772-6
Publication statusPublished - 2009
EventConference on Biomarkers in Brain Disease - Oxford, ENGLAND
Duration: 26 Jan 200928 Jan 2009

Publication series



ConferenceConference on Biomarkers in Brain Disease
CityOxford, ENGLAND


Dive into the research topics of 'AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this